Abstract
: We report a case of human epidermal growth factor receptor 2 positive (HER2+) breast cancer progressing to multiple metastases during several lines of anti-Her2 targeted therapy and chemotherapy, showing responses to TDM-1 and receiving clinical complete remission. The patient was diagnosed with HER2+ stage IIA invasive carcinoma of the left breast. The tumor progressed with skin invasion after neoadjuvant chemotherapy and continued progressing with sternum metastasis after trastuzumab-contained salvage treatment and dual-targeted therapy combined with chemotherapy. Afterward, the next-generation sequencing (NGS) test detected a PIK3CA mutation and the amplification of ERBB2. A third-line salvage therapy using everolimus and trastuzumab combined with chemotherapy consequently resulted in stable disease. After the therapy of TDM-1, the tumor received a durable complete clinical remission (cCR) that was maintained for 30 months. The regimen was initially TDM1 once 3 weeks for 19 months, then modified to once 4 weeks after the cCR statement lasted for 1year, and discontinued after another 10 months. During the medication, the patient regularly underwent the PET-CT every 3 to 4 months and was still disease-free until this report. This case delivers a view that keeping anti-HER2 therapy and adjusting regimens precisely according to gene sequencing can bring advanced HER2+ breast cancer to cCR.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.